Silo Pharma Signs Strategic Agreement with Fireblocks to Advance Crypto Treasury Strategy Acquisition and Security
Silo Pharma (Nasdaq: SILO), a developmental-stage biopharmaceutical and cryptocurrency treasury company, has partnered with Fireblocks as its institutional crypto treasury platform custodian. The strategic agreement aims to enhance Silo's digital asset management capabilities for Bitcoin, Ethereum, and Solana.
Fireblocks, which has facilitated over $6 trillion in secure transfers, will provide enterprise-grade security through its multi-layer framework, combining multi-party computation technology, Intel SGX, and deposit address authentication. This infrastructure will support Silo's long-term strategy for buying, staking, trading, and managing digital assets.
Silo Pharma (Nasdaq: SILO), una società biotecnologica in sviluppo e tesoreria di criptovalute, ha stretto una partnership con Fireblocks come custode della piattaforma istituzionale di tesoreria crypto. L'accordo strategico punta a migliorare le capacità di gestione degli asset digitali di Silo per Bitcoin, Ethereum e Solana.
Fireblocks, che ha facilitato oltre $6 trillion di trasferimenti sicuri, offrirà sicurezza a livello aziendale tramite un framework multi-livelli che combina tecnologia di calcolo multipartite, Intel SGX e autenticazione degli indirizzi di deposito. Questa infrastruttura sosterrà la strategia a lungo termine di Silo per acquistare, fare staking, negoziare e gestire asset digitali.
Silo Pharma (Nasdaq: SILO), una empresa en desarrollo en biotecnología y tesorería de criptomonedas, se ha asociado con Fireblocks como custodio de la plataforma institucional de tesorería de criptomonedas. El acuerdo estratégico tiene como objetivo mejorar las capacidades de gestión de activos digitales de Silo para Bitcoin, Ethereum y Solana.
Fireblocks, que ha facilitado más de $6 trillones de transferencias seguras, proporcionará seguridad de nivel empresarial mediante su marco de varias capas, que combina tecnología de computación multipartita, Intel SGX y autenticación de direcciones de depósito. Esta infraestructura apoyará la estrategia a largo plazo de Silo para comprar, hacer staking, operar y gestionar activos digitales.
Silo Pharma (Nasdaq: SILO), 개발 단계의 생물의약품 및 암호자산 보관고 회사는 기관용 암호화폐 보관 플랫폼의 수탁자로 Fireblocks와 파트너십을 맺었습니다. 이 전략적 협약은 비트코인, 이더리움, 솔라나에 대한 Silo의 디지털 자산 관리 능력을 강화하는 것을 목표로 합니다.
Fireblocks, 현재까지 6조 달러 이상의 안전한 이체를 원활하게 처리해 온 이 보안을 기업용 수준으로 제공할 것이며, 다층 프레임워크를 통해 다자간 계산(multi-party computation), Intel SGX, 예치 주소 인증을 결합합니다. 이 인프라는 Silo의 자산 구매, 스테이킹, 거래 및 관리에 대한 장기 전략을 뒷받침할 것입니다.
Silo Pharma (Nasdaq : SILO), une entreprise biopharmaceutique en phase de développement et trésorerie de cryptomonnaies, s’est associée à Fireblocks en tant que custodian de la plateforme institutionnelle de trésorerie crypto. Cet accord stratégique vise à améliorer les capacités de gestion des actifs numériques de Silo pour Bitcoin, Ethereum et Solana.
Fireblocks, qui a facilité plus de 6 trillions de dollars de transferts sécurisés, offrira une sécurité de niveau entreprise grâce à son cadre multi-niveaux combinant technologie de calcul multiparties, Intel SGX et authentification des adresses de dépôt. Cette infrastructure soutiendra la stratégie à long terme de Silo pour acheter, faire du staking, trader et gérer des actifs numériques.
Silo Pharma (Nasdaq: SILO), ein Entwicklungsunternehmen im Bereich Biopharmazie und Treuhandstelle für Kryptowährungen, hat eine Partnerschaft mit Fireblocks als Custodian der institutionellen Kryptotreasury-Plattform geschlossen. Die strategische Vereinbarung zielt darauf ab, Silos Fähigkeiten im Umgang mit digitalen Vermögenswerten für Bitcoin, Ethereum und Solana zu verbessern.
Fireblocks, das Transaktionen im Wert von über 6 Billionen US-Dollar sicher erleichtert hat, wird unternehmensweite Sicherheit durch sein mehrschichtiges Rahmenwerk bieten, das Technologien der Multi-Party Computation, Intel SGX und Authentifizierung von Depot-Adressen kombiniert. Diese Infrastruktur wird Silos Langzeitstrategie für den Kauf, das Staking, den Handel und die Verwaltung digitaler Vermögenswerte unterstützen.
Silo Pharma (Nasdaq: SILO)، شركة أدوية حيوية في طور التطوير وخزينة العملات المشفرة، قد تعاقدت مع Fireblocks كوصي على منصة الخزانة المؤسسية للعملات المشفرة. يهدف الاتفاق الاستراتيجي إلى تعزيز قدرات Silo في إدارة الأصول الرقمية لـ Bitcoin و Ethereum و Solana.
Fireblocks، التي سهّلت أكثر من 6 تريليون دولار من التحويلات الآمنة، ستوفر أماناً على مستوى الشركات من خلال إطار عمل متعدد الطبقات يجمع تكنولوجيا الحسابات متعددة الأطراف، ونظام Intel SGX، وتوثيق عناوين الإيداع. ستدعم هذه البنية الأساسية استراتيجية Silo الطويلة الأجل للشراء، والتخزين، والتعامل، وإدارة الأصول الرقمية.
Silo Pharma（纳斯达克：SILO），一家处于开发阶段的生物制药和加密货币财政管理公司，已与 Fireblocks 建立合作，成为其机构加密货币财政托管平台的托管方。该战略协议旨在提升 Silo 对 比特币、以太坊和 Solana 等数字资产的管理能力。
Fireblocks，已经促成超过 6 万亿美元 的安全转账，将通过其多层框架提供企业级安全，结合多方计算技术、Int el SGX 以及存款地址认证。这一基础设施将支持 Silo 长期的购买、质押、交易和数字资产管理策略。
- Partnership with Fireblocks, a proven platform that has processed over $6 trillion in transfers
- Access to institutional-grade security infrastructure for crypto asset management
- Expansion into cryptocurrency treasury management with focus on Bitcoin, Ethereum, and Solana
- Potential exposure to cryptocurrency market volatility
- Deviation from traditional pharmaceutical business model into crypto assets may increase company risk profile
Insights
Silo Pharma's partnership with Fireblocks signals serious entry into crypto treasury management, potentially diversifying revenue beyond pharma.
This partnership represents a significant strategic pivot for Silo Pharma, which identifies itself as both a "developmental-stage biopharmaceutical and cryptocurrency treasury company." The dual identity is noteworthy, as it appears Silo is diversifying beyond traditional pharma into digital asset management.
Fireblocks brings substantial credibility to this initiative, having facilitated over
The specific mention of Bitcoin, Ethereum, and Solana in their treasury strategy reveals a balanced approach: Bitcoin for value storage, Ethereum for its robust ecosystem, and Solana for its high-performance capabilities. The explicit mention of "staking" suggests Silo intends to generate yield from proof-of-stake assets, potentially creating a new revenue stream separate from their pharmaceutical operations.
This move represents a growing trend of public companies diversifying treasury holdings beyond cash. While MicroStrategy pioneered the Bitcoin treasury strategy, Silo's approach appears more diversified across multiple cryptocurrencies. The timing is interesting given increased institutional adoption of digital assets, though execution will determine whether this creates or destroys shareholder value.
Highly secure, institutional-grade infrastructure supports Bitcoin, Ethereum and Solana treasury strategy
SARASOTA, FL, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced that it has engaged Fireblocks, an enterprise platform for building blockchain applications and managing digital asset operations, as custodian for its institutional crypto treasury platform.
“Our engagement with Fireblocks is expected to ensure that our newly deployed crypto treasury platform is built with enterprise grade security and governance standards,” said Silo CEO Eric Weisblum. “We believe that Fireblocks’ proven institutional-grade infrastructure makes them the right partner to support our long-term strategy for buying, staking, trading, and managing our digital assets as we seek to build long-term value for our shareholders.”
Fireblocks is a globally recognized platform in the digital assets space, having facilitated the secure transfer of more than
“Partnering with Silo reflects our commitment to delivering secure, institutional-grade infrastructure that enables long-term value creation in digital assets,” said Ezra Solomon, Senior Manager of Corporate Strategy at Fireblocks. “We’re pleased to support their Bitcoin, Ethereum, and Solana treasury strategy with the technology and safeguards needed to buy, stake, and manage assets at scale.”
About Silo Pharma
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories. silopharma.com
About Fireblocks
Fireblocks is an easy-to-use platform to create new blockchain-based products and manage day-to-day digital asset operations. Exchanges, banks, PSPs, lending desks, custodians, trading desks, and hedge funds can securely scale their digital asset operations through the Fireblocks Network and MPC-based Wallet Infrastructure. Fireblocks serves thousands of organizations in the financial, payments, and web3 space, has secured the transfer of over
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.
Contact
800-705-0120
investors@silopharma.com
FAQ
What is the purpose of Silo Pharma's partnership with Fireblocks?
How much transaction value has Fireblocks processed to date?
What cryptocurrencies will Silo Pharma manage through the Fireblocks platform?
What security features does Fireblocks offer to Silo Pharma?
How does this partnership affect Silo Pharma's business model?
